Brief: GlycoMimetics - US FDA Clears Addition Of Time-Based Final Analysis To Phase 3 Study Of Uproleselan

Crescent Biopharma

15/06/2023 14:15

June 15 (Reuters) - GlycoMimetics Inc  GLYC.O :
    * GLYCOMIMETICS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION
CLEARS
ADDITION OF TIME-BASED FINAL ANALYSIS TO PIVOTAL PHASE 3 STUDY
OF UPROLESELAN IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    * GLYCOMIMETICS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION
CLEARS
ADDITION OF TIME-BASED FINAL ANALYSIS TO PIVOTAL PHASE 3 STUDY
OF UPROLESELAN IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    * GLYCOMIMETICS - FINAL ANALYSIS TO BE CONDUCTED AFTER
EARLIER OF
295 SURVIVAL EVENTS OR FDA-ALIGNED CUTOFF DATE; SEES TOPLINE
RESULTS BY END OF Q2 2024
    * GLYCOMIMETICS INC - FDA ALSO CLEARED ADDITION OF LANDMARK
EFS
AND OVERALL SURVIVAL ANALYSES AS SECONDARY ENDPOINTS

Source text for Eikon:  ID:nBwJWKYFa 
Further company coverage:  GLYC.O 

 (reuters.briefs@thomsonreuters.com)